Skip to main content

Co-Treatment With Copper Compounds Dramatically Decreases Toxicities Observed With Cisplatin Cancer Therapy And The Anticancer Efficacy Of Some Copper Chelates Supports The Conclusion That Copper Chelate Therapy May Be Markedly More Effective And Less Toxic Than Cisplatin Therapy

Buy Article:

$55.00 plus tax (Refund Policy)

Co-Administration of CuII chelates are reported to decrease life threatening Cisplatin [PtII(NH3)2(CL)2]-induced acute degenerative renal, gastrointestinal, thymic, and bone marrow states consistent with serious necrotizing and immunemediated inflammatory disease. Initially it was found that copper sulfate treatment completely prevented lethality as well as gastric and nephrotoxicity without compromising PtII(NH3)2(CL)2 antineoplastic activity, which led to suggestions that prior CuIItreatment be used clinically to prevent serious side effects of PtII(NH3)2(CL)2-treatment. In the course of these studies it was discovered that CuII-treatments alone inhibited neoplastic growth and increased survival of rat and mouse models of cancer. Subsequently it was discovered that a stable non-toxic and non-polar lipophilic chelate, CopperII 2(3,5-diisopropylsalicylate)4, caused redifferentiation of cultured neuroblastoma and mouse muscle-implanted mammary adenocarcinoma without neoplastic cell killing. Another stable non-toxic and non-polar lipophilic chelate, CopperII 2(3,5-ditertiarybutylsalicylate)4, was found to prevent Bax-initiated and caspases-3-activation mediated apoptosis. These remarkable observations are concluded to be due to enzyme-mimetic or modulating reactivities of CuII chelates and/or facilitation of CuII or I-dependent enzyme syntheses required to overcome inflammatory-neoplastic disease states. Further, approaches to treating neoplastic diseases by removal of Cu from tissues with ammonium tetrathiomolybdate in an anticopper approach to therapy are not well founded based upon existing scientific literature.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Cisplatin; ammonium tetrathiomolybdate; androstenedione synthesis; anti-inflammatory; anticancer; copper chelates; coppertetrathiomolybdate; redifferentiation

Document Type: Research Article

Affiliations: Division of Medicinal Chemistry,Department of Pharmaceutical Sciences, College of Pharmacy #522-3, University of Arkansas, Medical Sciences Campus, 4301 West Markham Street, Little Rock,Arkansas 72205-7122, USA.

Publication date: 2007-06-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more